- BARD1 Life Sciences (BD1) is gearing up to launch its first Molecular NET product, EXO-NET
- BD1 will unveil the research-use-only product at the International Society of Extracellular Vesicles virtual meeting, which runs from May 18 to 21
- EXO-NET works by capturing exosomes in a fast, accurate and scalable manner, from any biological sample, such as blood, urine and saliva
- Exosomes are small vesicles released by most cells into bodily fluids
- BD1 says the nanoparticles have “enormous” clinical and commercial potential in the diagnosis and treatment of diseases
- EXO-NET is designed to compete with existing exosome isolation and purification methods, which are reportedly time-consuming, not readily-scalable and frequently contaminated
- Shares in BARD1 Life Sciences are trading 1.21 per cent higher at $2.51
BARD1 Life Sciences (BD1) is gearing up to launch its first Molecular NET product, EXO-NET.
BD1 is an Australian diagnostics company focussed on developing best-in-class diagnostic solutions for healthcare professionals and patients, based on its BARD1, SubB2M and Molecular NET platforms.
The company is set to launch its product at the International Society of Extracellular Vesicles (ISEV) virtual annual meeting, which begins on May 18.
EXO-NET works by capturing exosomes in a fast, accurate and scalable manner, from any biological sample, such as blood, urine and saliva.
Exosomes refer to small vesicles released by most cells, including cancer cells, into bodily fluids. They are particularly important in cellular communication.
In fact, BD1 says these nanoparticles have “enormous” clinical and commercial potential in the diagnosis and treatment of diseases.
Following the launch, EXO-NET will be available for research-use only.
In this way, BARD1 is aiming to embed the product into the discovery, research and development phases for multiple exosome-based diagnostic and therapeutic applications, intended to lead to commercial sales and licensing opportunities.
The product has been developed to compete with existing exosome isolation and purification methods, which are reportedly time-consuming, not readily-scalable and frequently contaminated.
BARD1 Life Sciences CEO Dr Leaarne Hinch said the launch was a major milestone in the company’s commercial development of Molecular NET technology.
“BARD1 intends to leverage its next-generation EXO-NET technology to build a pipeline of exosome-based diagnostics for multiple indications,” Dr Hinch said.
“The company will also seek to partner with industry leaders to develop exosome therapeutic manufacturing solutions and companion diagnostics for new immunotheraputics,” she added.
BD1 Research and Development Manager and EXO-NET inventor Dr Emily Stein also commented on the launch.
“BARD1 has helped me realise the dream of bringing a commercial exosome isolation product to market that is really quick and easy for researchers to use and obtain results,” Dr Stein said.
According to BD1, Grand View Research projects the global exosome market will grow by over 18 per cent per annum to reach US$2.3 billion (around A$2.9 billion) by 2030.
The premier ISEV conference begins today and runs to May 21.
Shares in BARD1 Life Sciences are trading 1.21 per cent higher at $2.51 at 1:29 pm AEST.